Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (PAHC) has scheduled its second quarter financial results announcement for Wednesday, February 5, 2025, after market close. The company will follow up with a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time.
Investors can access the presentation through the company's investor relations website at https://investors.pahc.com. Additionally, participants can join via phone by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international calls, using conference ID 3927884. A replay of the webcast will be made available approximately two hours after the event concludes.
Phibro Animal Health (PAHC) reported strong Q1 FY2025 financial results with significant growth across key metrics. Net sales increased 13% to $260.4 million, while net income rose to $7.0 million. The company achieved a 64% increase in Adjusted EBITDA to $30.7 million. Animal Health segment showed impressive performance with 14% sales growth. The company updated its FY2025 guidance, projecting net sales of $1.05-1.10 billion and Adjusted EBITDA of $124-132 million. Additionally, Phibro announced the discontinuation of its atopic dermatitis project while maintaining focus on companion animal investments.
Phibro Animal Health (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on December 18, 2024, to stockholders recorded as of the close of business on November 27, 2024.
Phibro Animal Health (PAHC) has completed the acquisition of Zoetis' medicated feed additive portfolio and certain water-soluble products. The acquisition includes 37+ product lines across approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and a team of over 300 employees. The portfolio is expected to enhance Phibro's profitability, EBITDA margin, and Adjusted Earnings Per Share. The deal expands Phibro's species and product portfolios across cattle, swine, and poultry sectors, complementing their existing lineup of vaccines, nutritional specialties, and mineral nutrition.
Phibro Animal Health (Nasdaq: PAHC) has scheduled its first quarter financial results announcement for Wednesday, November 6, 2024, after market close. The company will host a conference call and webcast to discuss the results on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Investors can access the presentation through the company's investor website or by dialing in using the provided conference ID 3927884. A replay will be available approximately two hours after the event.
Phibro Animal Health (Nasdaq: PAHC) has announced its participation in the Morgan Stanley Annual Global Healthcare Conference. The company's Chief Financial Officer, Glenn David, and Chief Operating Officer, Larry Miller, will address financial analysts and investors on Thursday, September 5, 2024, at 1:05 PM ET at the New York Marriott Marquis.
The presentation will be available live via audio on the company's Investor Relations Website. For those unable to attend, a replay of the session will be archived and accessible on the same website. This event provides an opportunity for Phibro to engage with the financial community and share insights into its operations and strategy.
Phibro Animal Health (Nasdaq: PAHC) reported fourth-quarter and fiscal year 2024 results, showing mixed performance. Q4 Highlights: Net sales rose 7% to $273.2M; net income dropped $10.7M to $0.8M; diluted EPS fell by $0.26 to $0.02. Adjusted EBITDA increased 3% to $33.4M; adjusted net income rose 10% to $16.7M. Fiscal Year 2024 Highlights: Net sales grew 4% to $1.02B; net income decreased by $30.2M to $2.4M; diluted EPS dropped $0.75 to $0.06. Adjusted EBITDA fell 1% to $111.2M; adjusted net income dipped by 1% to $48.4M. Guidance for FY 2025: Net sales projected at $1.040B to $1.090B; adjusted EBITDA between $118M-$126M. CEO Jack Bendheim highlighted strength in Q4 performance and expects continued growth, especially in Animal Health.
Phibro Animal Health (Nasdaq: PAHC) has announced it will release its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after market close. The company will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time to discuss the results. Interested parties can access the webcast and presentation slides at https://investors.pahc.com. The call will also be available via phone, with separate numbers for U.S./Canada and international callers. A replay of the webcast will be available approximately two hours after the event concludes.
Phibro Animal Health (Nasdaq: PAHC) has announced a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. The dividend is set to be paid on September 25, 2024, to stockholders of record as of the close of business on September 4, 2024. This decision was made by the company's Board of Directors, demonstrating their commitment to returning value to shareholders. The consistent dividend payout suggests financial stability and confidence in the company's future performance.
Phibro Animal Health (Nasdaq: PAHC) has released its third annual Environmental, Social, and Governance (ESG) Report, highlighting 2023 achievements. The report emphasizes Phibro's commitment to enhancing animal health and nutrition to promote sustainability. Significant efforts include disease prevention, waste reduction, and resource conservation, which contribute to a safer, more affordable food supply. These initiatives align with the UN's 2030 Sustainable Development Goals (SDGs). The report underscores the importance of the One Health approach, emphasizing interconnections among the health of people, animals, and the planet. Phibro’s work in 2023 focused on reducing greenhouse gas emissions, enhancing food production efficiency, and supporting farmers' economic stability. This contributes to mitigating climate change and promoting food security. The company aims to continue driving sustainability and ethical growth, ensuring positive global contributions.